| 摘要 |
FIELD: medicine.SUBSTANCE: presented group of inventions refers to medicine. What is presented is a method for the prediction of a high probability of the therapeutic effect of high-affinity anti-VEGF antibody, particularly ranibizumab in the patient suffering age-related moist macular degeneration. What is presented is a kit comprising a first oligonucleotide and additional nucleotides specific for allele polymorphisms of matrix metalloprotease 25 (MMP25) gene corresponding to rs1064875. If the respective genotype contains AA or AG, the high probability of the effect of the above treatment is predicted.EFFECT: presented group of inventions provides the effective agents and methods for the prediction of the high probability of the effect of the treatment with the high-affinity anti-VEGF antibody in the patient with moist AMD.9 cl, 1 dwg, 5 tbl, 1 ex |
